📰 Biontech Fixvac News
Biontech Fixvac News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Biontech Fixvac. Real-time updates on events, politics, business and more.
May 6, 2024
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low...
May 6, 2024
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating...
May 6, 2024
Investegate announcements from BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
November 6, 2023
06.11.2023 - Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116Progress ...
August 31, 2023
/PRNewswire/ -- The "Global mRNA Cancer Vaccines Market Opportunity & Clinical Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.coms...
November 7, 2022
Investegate announcements from BioNTech SE, BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
March 9, 2022
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration with Regeneron to advance the Company’s FixVac candidate BNT116 in combination with Libtayo® (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). Under the terms of the ...
March 8, 2022
BioNTech and Regeneron plan to jointly conduct clinical trials evaluating FixVac candidate BNT116 in combination with Libtayo for the treatment of advanced non-small cell lung cancer (NSCLC)The development
June 30, 2021
Share MAINZ: BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). The study is evaluating the Company’s therapeutic cancer vaccine candidate BNT111 in combination with Libtayo® (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. BNT111 is the lead product candidate from BioNTech’s FixVac platform that t...